BPMC
Blueprint Medicines Corporation
68.46
USD
This page is just a preview of the data found in TrendSpider’s full version
Blueprint Medicines Corporation stock is up 16.31% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 November’s closed higher than October. In the last 8 Unusual Options Trades, there were 4 PUTs, 4 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 24 Oct 16:38 | 21 Jun, 2024 | 40.00 | 0 | ||
| 24 Oct 16:38 | 21 Jun, 2024 | 40.00 | 0 | ||
| 26 Oct 13:45 | 15 Dec, 2023 | 50.00 | 49 | ||
| 26 Oct 16:22 | 20 Dec, 2024 | 55.00 | 107 | ||
| 26 Oct 18:27 | 15 Dec, 2023 | 50.00 | 49 | ||
| 27 Oct 15:18 | 19 Jan, 2024 | 65.00 | 49 | ||
| 02 Nov 17:08 | 15 Dec, 2023 | 65.00 | 0 | ||
| 29 Nov 17:32 | 21 Jun, 2024 | 65.00 | 0 |
Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.
